TW505639B - (2-morpholinylmethyl)benzamide derivatives, their preparation and pharmaceutical composition containing the same - Google Patents
(2-morpholinylmethyl)benzamide derivatives, their preparation and pharmaceutical composition containing the same Download PDFInfo
- Publication number
- TW505639B TW505639B TW085106627A TW85106627A TW505639B TW 505639 B TW505639 B TW 505639B TW 085106627 A TW085106627 A TW 085106627A TW 85106627 A TW85106627 A TW 85106627A TW 505639 B TW505639 B TW 505639B
- Authority
- TW
- Taiwan
- Prior art keywords
- formula
- alkyl
- group
- compound
- acid
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 6
- QKWAMNZOEPKQBV-UHFFFAOYSA-N 2-(morpholin-2-ylmethyl)benzamide Chemical class NC(=O)C1=CC=CC=C1CC1OCCNC1 QKWAMNZOEPKQBV-UHFFFAOYSA-N 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 54
- -1 1-piperazinyl Chemical group 0.000 claims abstract description 40
- 125000001424 substituent group Chemical group 0.000 claims abstract description 21
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 6
- 150000001412 amines Chemical class 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 19
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- 238000011049 filling Methods 0.000 claims description 14
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 14
- 230000005176 gastrointestinal motility Effects 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 230000002496 gastric effect Effects 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical group [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 4
- 238000007126 N-alkylation reaction Methods 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 229910052786 argon Inorganic materials 0.000 claims description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 claims 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 claims 2
- 208000017228 Gastrointestinal motility disease Diseases 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical group O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims 1
- 229960001915 hexamidine Drugs 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N monoethyl amine Natural products CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 229910052649 zeolite group Inorganic materials 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 16
- 230000030136 gastric emptying Effects 0.000 abstract description 8
- 239000001257 hydrogen Substances 0.000 abstract description 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 abstract 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 19
- 238000007792 addition Methods 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 125000003118 aryl group Chemical group 0.000 description 9
- 125000003545 alkoxy group Chemical group 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 150000001204 N-oxides Chemical group 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 230000002079 cooperative effect Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 230000004899 motility Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- 241001674048 Phthiraptera Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- RWRIWBAIICGTTQ-UHFFFAOYSA-N difluoromethane Chemical compound FCF RWRIWBAIICGTTQ-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- XXQBEVHPUKOQEO-UHFFFAOYSA-N potassium superoxide Chemical compound [K+].[K+].[O-][O-] XXQBEVHPUKOQEO-UHFFFAOYSA-N 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 2
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- CUJPFPXNDSIBPG-UHFFFAOYSA-N 1,3-propanediyl Chemical group [CH2]C[CH2] CUJPFPXNDSIBPG-UHFFFAOYSA-N 0.000 description 1
- OMIVCRYZSXDGAB-UHFFFAOYSA-N 1,4-butanediyl Chemical group [CH2]CC[CH2] OMIVCRYZSXDGAB-UHFFFAOYSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
- 108091005479 5-HT2 receptors Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- PNKUSGQVOMIXLU-UHFFFAOYSA-N Formamidine Chemical compound NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010021518 Impaired gastric emptying Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000382353 Pupa Species 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 235000001537 Ribes X gardonianum Nutrition 0.000 description 1
- 235000001535 Ribes X utile Nutrition 0.000 description 1
- 235000016919 Ribes petraeum Nutrition 0.000 description 1
- 244000281247 Ribes rubrum Species 0.000 description 1
- 235000002355 Ribes spicatum Nutrition 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910001516 alkali metal iodide Inorganic materials 0.000 description 1
- 150000004973 alkali metal peroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000004974 alkaline earth metal peroxides Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940075894 denatured ethanol Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical class NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 208000001288 gastroparesis Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 235000015810 grayleaf red raspberry Nutrition 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- RRHJHSBDJDZUGL-UHFFFAOYSA-N lidamidine Chemical compound CN=C(N)NC(=O)NC1=C(C)C=CC=C1C RRHJHSBDJDZUGL-UHFFFAOYSA-N 0.000 description 1
- 229960005045 lidamidine Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000002751 molybdenum Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000001451 organic peroxides Chemical class 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- PFUVRDFDKPNGAV-UHFFFAOYSA-N sodium peroxide Chemical compound [Na+].[Na+].[O-][O-] PFUVRDFDKPNGAV-UHFFFAOYSA-N 0.000 description 1
- ILJOYZVVZZFIKA-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;hydrate Chemical compound O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 ILJOYZVVZZFIKA-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- OUOJIFQQBPKAMU-UHFFFAOYSA-N tetrazol-5-one Chemical compound O=C1N=NN=N1 OUOJIFQQBPKAMU-UHFFFAOYSA-N 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Description
經濟部中央標隼局員工消費合作社印製 五、發明説明(1) 本發明係關於新穎(2-嗎啉基甲基)苯甲醯胺衍生物,其 具有有利之胃腸能動性刺激性質,特別是其會加速胃排空 作用。其進一步關於包含彼等之醫藥組合物,製備該化合 物與組合物之方法,及其作爲醫藥之用途。 於1987年11月4日公告之歐洲專利Ep-A-0,243,959,揭 示多種(2-嗎啉基垸基)苯甲醯胺衍生物,作爲胃腸能動性 加強劑,與胃復安(metoclopramide)相較,其對於中樞神 經系統具有較少不利作用。 本發明化合物與該先前技藝化合物不同之處在於嗎啉基 部份之氪上取代基,意即在式(I)中之取代基L,不變地含 有羰基官能性。本發明化合物令人意外地顯示有利之胃腸 能動性刺激性質。更特定言之,其會加速胃排空作用。 本發明係關於新穎(2-嗎啉基甲基)苯甲醯胺衍生物,其 具有下式
N
OR1 R3〇 I II CH2—N一C
NH2 R2
、戎 > .· ^裝-----Γ 訂-------- (請先閲讀背面之注意事項再填寫本頁) L 八 \/二參、 其N-氧化物形式,藥學上可接受之加成鹽及化學異構 物形式,其中 R1爲Ci — 6垸基、C2-6歸基或C2-6炔基, R2爲虱、函基或Ci-6垸基績醯基胺基, R3爲氫或(^_6烷基; L爲下式基團 本紙張尺度適用中國國家樣準(CNs ) A4規格(210X297公釐) 505639 A7 B7 五、發明説明(2 ) 經濟部中央標準局員工消費合作社印製 〇 R4—C - Aik - (a); Ο R6 RJ—C—Ν-Alk-⑽巍; Ο y II 二 ' \ · R7一C一O—Aik—编 其中 各Aik係獨立爲Ci — u烷二基; R4爲虱,幾基,Ci_6垸基,C卜g垸氧基;胺基;單—或 二(Ci_6垸基)胺基;1-六氫吡啶基;被丨或2個取代基取 代之1-六氫吡啶基,取代基係選ICie垸基、Ci6烷氧 基、胺基、單-或二(Ci — 6垸基)胺基或芳基;i _四氫吡 咯基;被1或2個取代基取代之^四氫吡咯基,取代基係 選自Q-6垸基、垸氧基、胺基、單-或二(Ci 6燒基 )胺基或芳基;1 -六氫吡啡基;被1或2個取代基取代之 1-六氳啦W基,取代基係選自(:卜6烷基、(:卜6烷氧基、 胺基、單-或二(Ci—6垸基)胺基或芳基;六氫-1JJ-二氮 七園-1-基或被1或2個取代基取代之六氫-1JI-二氮七圜一 1-基’取代基係選自Ci-e垸基、Ci-6垸氧基、胺基、單 或二((:卜6垸基)胺基或芳基; R5與R7各獨立爲氫;Ci-e垸基;(^^垸氧基;胺基;單 或二(Ci-e燒基)胺基;卜六氫咄啶基;被1或2個取代基 取代之卜六氫吡啶基,取代基係選自(^_6垸基、q_6烷 氧基、胺基、單-或二(Cu垸基)胺基或芳基;1 -四氫 吼咯基;被1或2個取代基取代之1-四氫吡咯基,取代基 !lu----φ 裝-----.Γ 訂 ^-----Φ (請先聞讀背面之注意事項再填寫本頁)
505639 經濟部中央標準局員工消費合作社印製 A7 B7 五、發明説明(3) 係選自Ci-β烷基、Q —6烷氧基、胺基、單-或二(0卜6烷 基)胺基或芳基;1 -六氫吡畊基;被丨或2個取代基取代 之1-7T氫吡喷基,取代基係選自Ci 6烷基、Ci —6烷氧基 、胺基、單-或二(Cu烷基)胺基或芳基;六氫_ijj_二 氮七圜-1 _基或被1或2個取代基取代之六氫_1Η-二氮七 圜_ 1 -基,取代基係選自心―6烷基、Cl 6垸氧基、胺基 、單或一(Cl-6燒基)胺基或芳基; R6爲氫或(^-6垸基;及 芳基爲苯基,或被1、2或3個取代基取代之苯基,取代 基係選自ή基、Ci_6垸基或〇1_6垸氧基。 當在前文定義及於後文中使用時,於i-六氫吡畊基環上 之取代’可在4位置中之氮原子上,或在任何碳原子上; 於穴氮—乳七圜1基環上之取代,可在4位置中之敗 原子上,或在任何碳原子上;由基爲氟基、氣基、溴基及 碘基之總稱;Cn炫基係定義具有1至6個碳原子之直鏈與 分枝狀飽和烴基團,例如甲基、乙基、丙基、丁基、1一甲 基乙基、2-甲基丙基、戊基、己基及其類似物;C2 6埽基 係定義具有一個雙鍵並具有2至6個碳原子之直鍵或分枝狀 烴基團,例如乙婦基、2-丙烯基、3-丁烯基、2-丁缔基、 2-戊烯基、3-甲基-2-丁烯基及其類似物;C2 6炔基係定 義具有一個參鍵ϋ具有2至6個碳原子之直鏈或分枝狀烴基 團,例如乙炔基、2-丙炔基、3-丁炔基、2-丁炔基、2-戊 炔基、3-甲基-2-丁炔基及其類似物;垸二基係定義 含有1至6個碳原子之二價直鏈或分枝狀烴基團,例如i,2- 本紙張尺度適用巾國g|家標準(CNS ^見格(21。^ 297公釐) ----------- U.―_----------Γ1ΤIAW (請先閱讀背面之注意事項再填寫本頁) A7 ------- 五、發明説明(4) 乙垸二基、1,3-丙垸二基、丁燒二基、i,戍燒二基 、1,6-己垸-基及其分枝狀異構物;Ch2垸二基係定義 (請先閱讀背面之注意事項再填寫本頁) (:卜6燒二基及其具有7至12個碳原子之高碳同系物,例如 l7-庚燒一基、1,8_辛燒二基、1少壬垸二基、1,10 -癸 烷一基丨,11十一烷二基、ι,12-十二垸二基及其分枝狀 異構物。 如上文所連之藥學上可接受之加成Μ,係意謂包括式 )化合物能_成之具治療活性之無毒㈣與酸加成鹽形 式。此等酸加成卿式可合宜地經由以適當酸處理式⑴ 化合物之自由態驗开彡式而獲得。適當酸包括例如無機酸類 ,譬如氳自酸’如鹽酸或氫漠酸;硫酸;猶;鱗酸及類 似酸類;或有機酸,例如_、丙酸、餘献、乳酸、 丙酮酸、^:酸、丙二酸、琥始酸、順丁烯二酸、反丁缔二 酸、類果酸、酒石酸、檸檬酸、甲垸職、乙垸績酸、苯 績酸、對甲苯磺酸、環己垸胺基績酸、柳酸、對—胺基柳 酸、雙羥萘酸及類似酸類。反之,可使用鹼處理,使加成 鹽形式轉化成其自由態驗形式。 經濟部中央標準局員工消費合作社印裂 亦可將含有酸性質子之式(I )化合物,轉化成其無毒性 驗’意即金屬或胺加成㈣式,纟方式是使用適當有機與 無機驗處理。適當驗鹽形式包括例如銨鹽,鹼金屬與鹼土 金屬鹽,例如鋰、鈉、鉀、鎂、鈣鹽等,與有機鹼之鹽, 例如下星(benzathine)、Ν-甲基-D-葡萄糖胺、海巴胺鹽 ,及與胺基酸之鹽,例如精胺酸、離胺酸鹽等。反之,可 將鹼加成鹽形式以酸處理而轉化成其自由態酸形式。 本紙張尺度適i中國- 505639 A7 B7 五、發明説明(5) 於上文中使用之加成鹽一詞,亦包括式(I )化合物以及 其鹽能夠形成之溶劑合物。此種溶劑合物爲例如水合物、 醇化物及其類似物。 於前文使用之”立體化學異構物形式"一詞,係定義式 (I )化合物可具有之所有可能之異構物形式。除非另有提 及或指示,否則化合物之化學命名均表示所有可能立體化 學異構物形式之混合物,該混合物含有該基本分子結構之 所有非對映異構物與對掌異構物。更特定言之,立體原中 心可具有R-或S-組態;於二價環狀飽和基團上之取代基, 可具有順式-或反式-組態。式(j )化合物,其中以爲^^ 燁基者,可以E-與Z-形式之混合物存在,或成爲純E-形式 或純Z-形式。式(I )化合物之立體化學異構物形式,顯然 係意欲包含在本發明之範圍内。 一些式(I )化合物亦可以其互變異構形式存在。此種形 式雖然並未明確地顯示在上文式中,但係意欲包含在本發 明之範圍内。 經濟部中央標準局員工消費合作社印製 (請先閲讀背面之注意事項再填寫本頁) Φ 式(I)化合物之N-氧化物形式,係意謂包含以下之式(1) 化合物,其中一或數個氮原子係被氧化成所謂[氧化物, 特別是其中嗎啉-氮被N-氧化之N-氧化物。 於後又中任何時候使用時,式(j )化合物一詞係意謂亦 包含其N·氧化物形式、藥學上可接受之加減及所有立體 異構物形式。 式(I )化合物之特定族群,係爲其中適用一或多個下列 限制者:
505639 A7 B7 五、發明説明(6) a) {^爲^^烷基,較佳爲甲基; b) R2爲鹵基,較佳爲氣基; c) R3爲氫; d) L爲式(a)基團; e) Aik爲C卜6烷二基;較佳爲1,3-丙烷二基、1,4-丁燒 二基或1,5-戊烷二基。 較佳化合物爲以下之式(I )化合物,其中R1爲曱基,R2 爲氣基,R3爲氫,Aik爲1,3-丙垸二基、1,4-丁垸二基或 1,5-戊烷二基,及L爲式(a)基團,其中以爲^^燒基、 二(Ci-6垸基)胺基或1-四氫吡咯基0 最佳化合物爲 2- [[(4-胺基-5-氣基-2-甲氧苯甲醯基)胺基]甲基]-N,N-二乙基-4-嗎啉丁醯胺; [胺基-5_氣基-2-曱氧基-N-[ [4-[4-氧基-4-(1-四氫吼咯 基)丁基]-2-嗎咻基]甲基]苯甲醯胺;其藥學上可接受之 加成鹽及立體化學異構物。 於後文中任何時候使用時,R1至R3及L均如式(I )中之 定義,除非另有述及。 經濟部中央標準局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) 於下述製備中,可將反應產物自反應混合物中分離,及 若需要則根據此項技藝中一般已知之方法進一步純化,例 如萃取、蒸餾、結晶、研製及層析。 式(I )化合物可一般性地根據歐洲專利EP-A-0,243,959 中所述之方法製備。 特定言之,式(I )化合物可經由以式(ΙΠ)中間物使式( 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) ⑽639 A7 B7
+ L—W 五、發明説明(7 ) Π)嗎咻衍生物N-烷基化而製成,其中w爲反應性脱離基, 例如自基,如氣基、溴基或碘基,或磺醯氧基,如甲垸續 醯氧基、甲苯磺醯氧基及類似脱離基。 棒®\ . tn -
N-烷基M J an) 該N-燒基化作用可合宜地在對反應呈惰性之溶劑中進行 ’例如N,N-二甲基甲酿胺或甲基異丁基酮,於適當驗存在 下’例如碳酸銷或二乙基乙胺,其可用以捕獲反應過程期 間所釋出之酸。在一些情況中,添加碘化物鹽,較佳爲鹼 金屬碘化物,或冠狀醚,例如1,4,7,10,13,16-六氧環十 八垸及其類似物,均可能適合。攪拌及提高溫度可提高反 應速率。此外,可有利地在惰性大氣下,譬如在不含氧之 氬氣或氮氣下,進行該N-烷基化作用。 可進一步製備式(I )化合物,其方式是根據技藝上已知 之基團轉換反應’使式(I )化合物互相轉化。 亦可將式(I )化合物轉化成其相應之N-氧化物形式,其 係按照技藝上已知之程序,使三價氪轉化成其心氧化物形 式。該N-氧化反應可一般性地經由將式(I )起始物質與適 當有機或無機過氧化物反應而進行。適當無機過氧化物包 括例如過氧化氫,鹼金屬或鹼土金屬過氧化物,例如過氧 化鈉、過氧化鉀;適當有機過氧化物可包括過氧酸,例如 !:----•裝-----1'玎—-----0 (請先閱讀背面之注意事項再填本頁) 經濟部中央標準局員工消費合作社印製
經濟部中央標準局員工消費合作社印製 505639 A7 ___ B7 五、發明説明~ — 苯碳過氧酸或鹵基取代之苯碳過氧酸,例如3-氣苯碳過氧 酸,過氧烷酸,例如過氧醋酸,烷基氫過氧化物,例如氫 過氧化第三-丁垸。適當溶劑爲例如水,低碳烷醇類,例 如乙醇及其類似物,烴類例如甲苯,酮類例如2-丁酮,鹵 化烴類例如二氣甲烷,及此等溶劑之混合物。 用以合成本發明化合物所需要之試劑及式(11)與(111) 之中間物,係爲易於市購而得或可根據已知程序製備。例 如ΕΡ-Α-0,243,959係描述一些式(II)中間物之製備,及在 1989年3月29日公告之歐洲專利ΕΡ-Α-0,309,043係插述一 些式(ΙΠ)中間物之製備。 式(I )化合物、Ν-氧化物形式、藥學上可接受之加成鹽 及其可能的立體異構物形式,均具有有利之胃腸能動性刺 激性質。特定Τ之,本發明化合物對於胃排空作用顯示出 顯著能動性加強作用。後述性質可藉由後文所述”於老鼠 中液體餐飲之胃排空作用,,試驗中所獲得之結果証實,且 可進一步藉由”在有知覺狗中,於投予利達脒(lidamidine )後,無熱量餐飲之胃排空作用"試驗証實。 此外,大部份本發明式(I )化合物、N-氧化物形式、藥 學上可接受之加成鹽及其可能的立體異構物形式,均顯示 與幾色胺能-5HTA5-羥色胺能-5HT2受體之極少或無受 體結合親和力,及具有極少或無多巴胺能拮抗活性。 蓉於主題化合物之有用胃腸能動性加強性質,故可將其 調配成供投藥目的用之各種形式。 可引用所有經常用於系統投藥之組合物,作爲適當醫藥 本紙張尺度顧巾國目家縣(CNS ) Μ規格(2獻297公羡) ----_裝-----:Γ 訂^------0 (請先閱讀背面之注意事項再填寫本頁) 505639 經濟部中央標準局員工消費合作社印裝 A7 B7 五、發明説明(9 ) 組合物。爲製備本發明之醫藥組合物,係將作爲活性成份 之治療上有效量之特定化合物,視需要呈加成鹽形式,與 藥學上可接交之栽劑,合併成密切互混物,其可採取極多 種形式,依欲供投藥之製劑形式而定。此等醫藥組合物係 令人滿意地呈單一劑量形式,較佳地適合供口服投藥或藉 非經腸注射使用。例如,在製備呈口服劑量形式之組合物 中,可採用任何常用醫藥媒質,在譬如懸浮液、糖漿、酏 劑及溶液之口服液體製劑之情況中,係爲例如水、二醇類 、油類、醇類及其類似物;或在粉末、丸劑、膠囊及片劑 之情況中,爲固體载劑,譬如殿粉、糖、高嶺土、潤滑劑 、黏合劑、崩解劑及其類似物。由於片劑與膠囊易於投藥 ,故其係代表最有利之口服劑量單位形式,於此情況中顯 然係採用固體醫藥载劑。對非經腸組合物而言,载劑通常 包含無菌水,至少是大部份,惟其他成份,例如用以幫助 溶解者,亦可包含在内。例如,可製備可注射溶液,其中 载劑包括鹽水落液、葡萄糖溶液或鹽水與葡萄糖溶液之混 合物。亦可製備可注射懸浮液,於此種情況中,可採用適 當液體载劑、懸浮劑及其類似物。式(j )化合物之加成鹽 ’由於其増加之水溶解度,高於其相應之自由態鹼或酸形 式’故顯然更適用於含水組合物之製劑中。 尤其有利的是,調配前述醫藥組合物呈劑量單位形式, 以提供投藥簡易性及劑量均勻性。於本專利說明書及本文 申請專利範圍中之劑量單位形式,係指適合作爲單一劑量 之物理上分開之單位,各單位含有經計算以產生所要治療 ί — .----_裝-----訂------Φ (請先聞讀背面之注意事項再填寫本頁} -11 -
505639 A7 B7 五、發明説明io ) 作用之預定量活性成份,並伴隨著所需要之醫藥载劑。此 種劑量單位形式之實例,係爲片劑(包括經刻劃或塗層片 劑)、膠囊、丸劑、粉末包、扁片、可注射溶液或懸浮液 、茶匙量藥、大匙量藥等,及其分離多重藥劑。 鑒於本發明化合物刺激胃腸系統能動性之能力,且特別 是其加速胃排空作用之能力’故主題化合物可用以使患有 經擾亂能動性病患中之胃與腸排空作用正常化或改良,該 病症例如食道及/或胃及/或小腸及/或大腸之減退蠕動 〇 鑒於式(I )化合物之利用性,故本發明亦提供一種治療 患有胃%系統能動性病症之溫血動物之方法,該病症例如 食道炎、胃輕癱、吼積性消化不良、非潰瘍·性消化不良、 假阻塞、受傷害之結腸變遷及類似病症。該方法包括對溫 血動物系統性投予有效胃腸刺激量之式(I )化合物。因此 ,提供式U)化合物作爲醫藥之用途,且特別是式(〖)化合 物於製造醫藥以治療涉及減退的胃腸能動性症狀上之用途 〇 經濟部中央標準局員工消費合作社印製 熟請此種能動性病症之治療者,可從後文所提出之試驗 結果決定出有效刺激量。日服有效量爲约〇·;[毫克/公斤 至约40毫克/公斤體重,更佳爲约0.5毫克/公斤至約5毫 克/公斤體重。治療方法亦可包括在每天二至四次攝取之 間之服用法下,投予活性成份。 下述實例係欲予説明而非限制本發明之範圍。 -12 - 中國 ϋ標CNS ) A4 規格(21GX297公釐) ' - 505639 A7 __B7_ 五、發明説明h ) ~~' —^ 實驗部份 A.式(I)化合物之製備 實例1 將4-氣-N,N-二乙基丁醯胺(2·1·6克)、4-胺基-5 —氣— 甲戰基-.(2-嗎琳基甲基)苯甲酿胺(3克)(按歐洲專利Ερ 一 Α-0,243,959中所述之程序製成)及碳酸鈉(158克)在Ν,Ν一 二甲醯胺(90毫升)中之混合物,於7(TC下攪拌48小時。蒸 發溶劑並將水添加至殘留物中。將此混合物以二氣甲垸萃 取兩次’並將合併之萃液以水洗滌,乾燥,過濾及蒸發溶 劑。殘留物於矽膠上藉管柱層析純化(溶離劑:chci3/ CH3〇H 95/5)。收集第一份溶離份,並蒸發溶劑。使殘留 物在2-丙醇與二異丙基醚中轉化成其麼酸鹽。將此鹽渡出 並自乙腈結晶。濾出沉殿物並乾燥,產生1·43克(30.4%) (±)-2-[[(4-胺基-5-氣-2-甲氧苯甲醯基)胺基]甲基]一1 Ν-二乙基-4-嗎咻-丁醯胺單鹽酸鹽半水合物(化合物1 ;熔 點 122.2°C) 〇 以類似方式,製備表1中之化合物〇 表1 經濟部中央標準局員工消費合作社印製
本紙張尺度適用中國國家標準(CNS ) A4規格(21〇Χ297公釐) 505639 A7 B7 五、發明説明i2 ) 化合物编號 L 物理數據(熔點,°C) 1 Ν,Ν-二乙基丁醯胺 (±)/HCl.l/2H20/122.2 2 (±)/129·2 六氫啦井基氧基戊基 (土 )/2ΗΠ·1/2Η20/257·4 4 1 卜六氫吡啶基)丁基 (土 )/118.7 5 2-(4:^墓-卜六氫吡喷基)-2-氧乙基 (土)/H20/118.7 6 6-(4-甲基-卜六氫吡畊基)-6-氧己基 (± )/123.8 7 4-氧基-4-(4-苯基-1-六氳吡畊基)丁基 (±)/224·2 8 4-氧基-4-(1-四氩吡格基)丁基 (土)/120.0 (請先閲讀背面之注意事項再
B.藥理學實例 實例2 : ”於老鼠中液體餐飲之胃排令作用”試驗 、^1 經濟部中央標準局員工消費合作社印製 根據最初由Reynell與Spray所設計方法(j· physi〇1, ML 452-456(1956))之修正變型方法,度量老鼠中之胃 棑空作用。於24小時期間,剝奪老鼠食物並隔離在個別蘢 子中。試驗餐飲’係由200毫克酚紅在4〇亳升蒸館水中之 溫熱懸浮液所組成,其係在皮下投予式(j )化合物或鹽水 後半小時,藉口腔插管法給予(〇.4亳升/老鼠)。於半小 時後,藉頸部脱位使老鼠犧牲。然後藉剖腹術使胃曝露出 ,迅速在幽Η與賁Η處結紮,並移除之。將胃切碎,並以 100¾升0.1Ν虱氧化納萃取其内容物。以比色方式,在Mg 毫微米下,於分絲度計巾檢測此萃液之岐含量。於睡 水處理之動物中,獲得平均値h41消先單位。表2顯示^ 試驗讀2.5毫克/公斤制化合物後之平均消光單位。 本紙張尺度適用) Α4規格( -14 ~ 505639 五、發明説明任3 經濟部中央標準局員工消費合作社印製 表2 化合物編號 平均消光單位 1 0.63 2 1.01 3 1.12 4 0.89 5 1.35 6 0.98 7 0.71 8 0.52 C.組合物管例 在整個此等實例中所使用之•,活性成份"(Α·Ι·),係關於 式(I )化合物、Ν-氧化物、藥學上可接受之加成鹽或其立 體化學異構物形式。 例3 : 口服浓洛 將9克4-羥基苯甲酸甲酯與1克4-羥基苯甲酸丙酯溶解於 4升沸騰之純水中。於3升此溶液中,首先溶解1〇克2,3-二 羥基丁二酸,然後是20克Α· I。將後述溶液與前述溶液之 其餘部份合併,並於其中添加12升1,2,3-丙三醇與3升花 -15 本紙張尺度適用中國國家標準(CNS ) M規格(2丨0><297公釐) (請先聞讀背面之注意事項再填寫本頁}
I n I 505639 A7 B7 五、發明説明《4 ) 經濟部中夬榡隼局員工消費合作、社印裂 楸醇70%溶液。將40克糖精鈉溶解於〇 5升水中,並添加 2毫升紅複盆子與2毫升醋栗精。將後述溶液與前者合併, 添加水足量至20升,提供每茶匙量(5毫升)包含5毫克A I 之口服溶液。將所形成之溶液充埽在適當容器中。 置A 4 :薄膜%霜片劑 先劑核芯之製備 將100克Α·Ι·、570克乳糖及2〇〇克澱粉之混合物充分混 合,接著使用5克硫酸十二酯鈉與1〇克聚乙烯基四氫吡咯 酮在约200毫升水中之溶液濕化。將濕粉末混合物篩濾、 乾燥及再一次篩濾。然後添加1〇〇克微晶性纖維素及15克 氫化植物油。將整體充分混合並壓縮成片劑,獲得1〇,〇〇〇 個片劑,各包含10毫克活性成份。 塗層 於10克甲基纖維素與75毫升變性乙醇之溶液中,添加5 克乙基纖維素與150毫升二氣甲烷之溶液。然後,於其中 添加75毫升二氣甲燒與2.5毫升1,2,3 _丙三醇。使1〇克聚 乙二醇熔融,並溶解於75毫升二氣曱烷中。將後述溶液添 加至前者中,然後添加2.5克十八酸鎂、5克聚乙烯基四氣 呲咯酮及30毫升濃的處理著色懸浮液,並使整體均化。將 片劑核芯在塗覆裝置中,以如此獲得之混合物塗覆。 實例5:可注射溶液 將1· 8克4-羥基苯甲酸甲酯與〇.2克4-羥基苯甲酸丙酯溶 -16 - 本紙張尺度適用中國國家標率(CNS ) Α4規格(210X297公釐) (請先閱讀背面之注意事項再填寫本頁)
訂 I 1- -1 - -I · ·....... -I . 505639 A7 B7 五、發明説明i5 ) 解於約0.5升煮沸之注射用水中。於冷卻至约50°C後,添 加4克乳酸、0.05克丙二醇及4克A.I.,同時攪拌。使溶液 冷卻至室溫,並補充注射用水足量至1升體積,獲得4毫克 A.I./毫升之溶液。將此溶液藉辱濾殺菌(美國藥典XVII 第811頁),並充填在無菌容器中。 經濟部中央標準局員工消費合作社印製 17 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐)
Claims (1)
- 505639 ,_丨--------------- 公告木 A8 B8 t C8 D8 月》曰丨夕正 ^---SAi 六、申請專利範圍 專利申請案第85106627號 ROC Patent Appln. No.85106627 修正之申請專利範圍中文本-附件㈠ Amended Claims in Chinese - Enel.(I) (民國89年10月Z—日送呈) (Submitted on October Z ? 2000) 1. 一種具有下式之化合物 OR1經濟部智慧財產局員工消費合作社印製 其藥學上可接受之加成鹽及立體化學異構物形式,其中 R1為Cw烷基; R2為鹵基; R3為氩; L為下式基團 〇 • R4—C-Alk- (a);其中 各Aik係獨立為(^.12烷二基; R為鼠,Ck烧基,胺基,早·或二(Ck烧基)胺基,1-六 鼠^比17定基,1-四氮吼13各基;1-六氮σ比1:1井基或被1或2個選自 於Ci_4烷基或苯基之取代基所取代之1-六氫吡畊基。 -18 - (請先閱讀背面之注意事項再填寫本頁)本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) J8S166 olaim-C^ 六、申請專利範圍 A8B8C8D8 .Γ請專利範圍第1項之化合物,其中該化合物係選 2-[[(4-胺基-5-氯基_2_甲氧笼田 乙基冰嗎咐丁醯胺; 基)胺基]甲基]灿-二 4-胺基-5-氯基_2_甲氧基| 丁基]-2-嗎喷基]曱基]苯甲酿胺.&土_ _ 1•四虱吼口各基) 其藥學上可接k域料讀 3. -種供治療涉及胃腸能動 于異構物形式。 物,其包括醫藥上可接受之以=台丙療症:醫藥組合 4. 根據申„專利範圍第…項之 龄及胃腸能動性降低之病症的^使用4作為供治ίΞΪΓ艮據申請專利範圍第1項之化合物之方法,其 於^性條件下且於叱至150t之溫度 化合物將式(II)中間物㈣基化, 吏用式OT) 5. 經濟部智慧財產局員工消費合作社印製 Γ\Ν Η (H) R3 〇 > X CH】—Ν一CL一 W m N-烷基化 © =中R、R2、R3及L係如申請專利範圍第丨項中所界 疋者且W係為選自於鹵基與石黃酿氧基中之反應性脫 離基, 19- (請先閱讀背面之注音?事項再填寫本頁}經濟部智慧財產局員工消費合作社印製 505639 A8 B8 C8 D8 六、申請專利範圍 及視需要藉官能基轉換反應,使式(I)化合物互相轉化; 及若需要則將式(I)化合物轉化成藥學上可接受之酸或 驗加成鹽,或反之,使用驗或酸,使酸或驗加成鹽轉化 成自由態鹼或自由態酸形式;及/或製備其立體化學異 構物形式。 -20- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95201350 | 1995-05-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW505639B true TW505639B (en) | 2002-10-11 |
Family
ID=8220318
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW085106627A TW505639B (en) | 1995-05-23 | 1996-06-04 | (2-morpholinylmethyl)benzamide derivatives, their preparation and pharmaceutical composition containing the same |
Country Status (18)
Country | Link |
---|---|
US (1) | US6100262A (zh) |
EP (1) | EP0827500B1 (zh) |
JP (1) | JPH11505815A (zh) |
KR (1) | KR100446099B1 (zh) |
AT (1) | ATE208766T1 (zh) |
AU (1) | AU710037B2 (zh) |
CA (1) | CA2220140C (zh) |
DE (1) | DE69617001T2 (zh) |
DK (1) | DK0827500T3 (zh) |
ES (1) | ES2167563T3 (zh) |
IL (1) | IL118379A (zh) |
MY (1) | MY117938A (zh) |
NO (1) | NO309900B1 (zh) |
NZ (1) | NZ309065A (zh) |
PT (1) | PT827500E (zh) |
TW (1) | TW505639B (zh) |
WO (1) | WO1996037486A1 (zh) |
ZA (1) | ZA964100B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1678594A (zh) | 2000-09-29 | 2005-10-05 | 葛兰素集团有限公司 | 用于治疗炎性疾病的吗啉-乙酰胺衍生物 |
UA77515C2 (en) * | 2002-04-04 | 2006-12-15 | Diazabicyclo alkane derivatives possessing neuroldnin-nk1 receptor antagonistic activity | |
TWI423967B (zh) * | 2008-02-21 | 2014-01-21 | Dainippon Sumitomo Pharma Co | 醯胺衍生物及含有其之醫藥組合物 |
IL277071B1 (en) | 2018-03-08 | 2024-03-01 | Incyte Corp | Aminopyrizine diol compounds as PI3K–y inhibitors |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
CN110938068B (zh) * | 2019-11-06 | 2022-12-23 | 广东东阳光药业有限公司 | N-(吗啉-2-基甲基)酰胺衍生物及其用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4870074A (en) * | 1986-04-30 | 1989-09-26 | Dainippon Pharmaceutical Co., Ltd. | Substituted benzamide derivatives, for enhancing gastrointestinal motility |
KR970702247A (ko) * | 1994-03-30 | 1997-05-13 | 고야 마사시 | 벤조산 화합물 및 이들의 약제로서의 용도(benzoic acid compound and use thereof as medicine) |
-
1996
- 1996-05-15 DK DK96916121T patent/DK0827500T3/da active
- 1996-05-15 CA CA002220140A patent/CA2220140C/en not_active Expired - Lifetime
- 1996-05-15 ES ES96916121T patent/ES2167563T3/es not_active Expired - Lifetime
- 1996-05-15 DE DE69617001T patent/DE69617001T2/de not_active Expired - Lifetime
- 1996-05-15 JP JP8535361A patent/JPH11505815A/ja active Pending
- 1996-05-15 EP EP96916121A patent/EP0827500B1/en not_active Expired - Lifetime
- 1996-05-15 WO PCT/EP1996/002141 patent/WO1996037486A1/en active IP Right Grant
- 1996-05-15 PT PT96916121T patent/PT827500E/pt unknown
- 1996-05-15 NZ NZ309065A patent/NZ309065A/xx unknown
- 1996-05-15 AU AU58992/96A patent/AU710037B2/en not_active Ceased
- 1996-05-15 KR KR1019970707669A patent/KR100446099B1/ko not_active IP Right Cessation
- 1996-05-15 AT AT96916121T patent/ATE208766T1/de not_active IP Right Cessation
- 1996-05-21 MY MYPI96001904A patent/MY117938A/en unknown
- 1996-05-22 ZA ZA9604100A patent/ZA964100B/xx unknown
- 1996-05-22 IL IL11837996A patent/IL118379A/xx not_active IP Right Cessation
- 1996-06-04 TW TW085106627A patent/TW505639B/zh active
-
1997
- 1997-11-21 NO NO975342A patent/NO309900B1/no unknown
-
1999
- 1999-09-22 US US09/401,729 patent/US6100262A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DK0827500T3 (da) | 2002-02-25 |
EP0827500B1 (en) | 2001-11-14 |
WO1996037486A1 (en) | 1996-11-28 |
DE69617001D1 (de) | 2001-12-20 |
KR100446099B1 (ko) | 2004-11-10 |
PT827500E (pt) | 2002-04-29 |
JPH11505815A (ja) | 1999-05-25 |
CA2220140A1 (en) | 1996-11-28 |
CA2220140C (en) | 2008-02-12 |
AU5899296A (en) | 1996-12-11 |
MY117938A (en) | 2004-08-30 |
IL118379A (en) | 1999-12-31 |
DE69617001T2 (de) | 2002-07-11 |
ZA964100B (en) | 1997-11-24 |
ES2167563T3 (es) | 2002-05-16 |
AU710037B2 (en) | 1999-09-09 |
NO309900B1 (no) | 2001-04-17 |
NZ309065A (en) | 1999-06-29 |
US6100262A (en) | 2000-08-08 |
NO975342D0 (no) | 1997-11-21 |
IL118379A0 (en) | 1996-09-12 |
KR19990008144A (ko) | 1999-01-25 |
NO975342L (no) | 1997-11-21 |
EP0827500A1 (en) | 1998-03-11 |
ATE208766T1 (de) | 2001-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW504510B (en) | 2,4-diaminopyrimidine derivatives | |
TW386081B (en) | Opioid compounds | |
TWI225485B (en) | Piperazine derivatives of formula (I), pharmaceutical composition for the treatment of conditions mediated by tachykinins of a mammal comprising them, and processes for preparing the same | |
TW201308B (zh) | ||
TWI306402B (en) | N-[phenyl(piperidin-2-yl)methyl]benzamide derivatives, their preparation and their application in therapy | |
CN108697715A (zh) | 包含帽依赖性核酸内切酶抑制剂及抗流感药的组合的流感治疗用药物 | |
JP4643141B2 (ja) | 肥満治療用のmchアンタゴニスト | |
CN103929961A (zh) | 化合物及其治疗应用 | |
TW201124378A (en) | Indole compounds and pharmaceutical use thereof | |
TW312693B (zh) | ||
CN103415289A (zh) | 前神经原性化合物 | |
CN108602813A (zh) | 作为apj受体激动剂的杂芳基羟基嘧啶酮 | |
HU225810B1 (en) | Therapeutically effective tropane derivatives, process for their preparation pharmaceutical compositions containing them and their use | |
TW492960B (en) | Azetidine derivatitives, relevant processes of manufacture and the uses thereof as tachykinin inhibitors | |
CN110256440A (zh) | 酞嗪异噁唑烷氧基衍生物、其制备方法、药物组合物和用途 | |
TW200811165A (en) | N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | |
CN109890388A (zh) | 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂 | |
CN109862893A (zh) | 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂 | |
CN110035995A (zh) | 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂 | |
CN107530304A (zh) | Olig2活性的抑制 | |
CN109863139A (zh) | 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂 | |
TW200526573A (en) | Organic compounds | |
TW505639B (en) | (2-morpholinylmethyl)benzamide derivatives, their preparation and pharmaceutical composition containing the same | |
TW490465B (en) | Enterokinetic benzamide, the preparation process and the pharmaceutical compositions thereof | |
TW201100431A (en) | N-[(6-azabicyclo[3.2.1]oct-5-yl)arylmethyl]heterobenzamide derivatives, preparation and therapeutic use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent |